Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes

Molecular Vision

Volumn 19, Issue , 2013, Pages 54-61

  Gross, Nikolai ^a   Ranjbar, Mahdy ^a   Evers, Charlotte ^a   Hua, Jing ^a   Martin, Gottfried ^a   Schulze, Brita ^b   Michaelis, Uwe ^b   Hansen, Lutz L ^a   Agostini, Hansjürgen T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MediGene AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE DEXTRAN; LIPOSOME; PACLITAXEL; TETRAMETHYLRHODAMINE; VERTEPORFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; ENCAPSULATION; FEASIBILITY STUDY; LASER COAGULATION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; PACLITAXEL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PRODRUGS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84872852457     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26:859-70. [PMID: 17031284].
2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358:2606-17. [PMID: 18550876].
3. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003; 105:561-7. [PMID: 12712451].
4. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-13. [PMID: 9525983].
5. Hua J, Gross N, Schulze B, Michaelis U, Bohnenkamp H, Guenzi E, Hansen LL, Martin G, Agostini HT. In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. Mol Vis 2012; 18:1045-54. [PMID: 22605917].
6. Eichhorn ME, Luedemann S, Strieth S, Papyan A, Ruhstorfer H, Haas H, Michaelis U, Sauer B, Teifel M, Enders G, Brix G, Jauch K-W, Bruns CJ, Dellian M. Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer Biol Ther 2007; 6:920-9. [PMID: 17534143].
7. Herber-Jonat S, Mittal R, Gsinn S, Bohnenkamp H, Guenzi E, Schulze A. Comparison of lung accumulation of cationic liposomes in normal rats and LPS-treated rats. Inflamm Res 2011; 60:245-53. [PMID: 20938712].
8. Koz OG, Ozhuy S, Tezel GG, Karaman N, Unlu N, Yarangumeli A, Kural G. The effect of paclitaxel on conjunctival wound healing: a pilot study. J Glaucoma 2007; 16:610-5. [PMID: 18091179].
9. van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ. Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1985; 26:1140-7. [PMID: 2862129].
10. Daniels SA, Coonley KG, Yoshizumi MO. Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228:513-6. [PMID: 1979953].
11. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57:81-6. [PMID: 8988045].
12. Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 2008; 122:452-60. [PMID: 17918179].
13. Strieth S, Eichhorn ME, Werner A, Sauer B, Teifel M, Michaelis U, Berghaus A, Dellian M. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin Cancer Res 2008; 14:4603-11. [PMID: 18628475].
14. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003; 9:2335-41. [PMID: 12796403].
15. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 2003; 120:476-82. [PMID: 12603862].
16. Koudelka S, Turánek J. Liposomal paclitaxel formulations. J Control Release 2012; 163:322-34. [PMID: 22989535].
17. Das RA, Romano A, Chiosi F, Menzione M, Rinaldi M. Combined treatment modalities for age related macular degeneration. Curr Drug Targets 2011; 12:182-9. [PMID: 20887244].
18. Chan WM, Lim T-H, Pece A, Silva R, Yoshimura N. Verteporfin PDT for non-standard indications-a review of current literature. Graefes Arch Clin Exp Ophthalmol 2010; 248:613-26. [PMID: 20162298].
19. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007; 29:1850-61. [PMID: 18035187].
20. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005; 50:167-82. [PMID: 15749307].
21. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer 1994; 69:833-9. [PMID: 8180011].
22. Tobe T, Ortega S, Luna JD, Ozaki H, Okamoto N, Derevjanik NL, Vinores SA, Basilico C, Campochiaro PA. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 1998; 153:1641-6. [PMID: 9811357].
23. Odergren A, Ming Y, Kvanta A. Photodynamic therapy of experimental choroidal neovascularization in the mouse. Curr Eye Res 2006; 31:765-74. [PMID: 16966149].
24. Eichhorn ME, Becker S, Strieth S, Werner A, Sauer B, Teifel M, Ruhstorfer H, Michaelis U, Griebel J, Brix G, Jauch K-W, Dellian M. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther 2006; 5:89-96. [PMID: 16357513].
25. Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci 2008; 49:662-70. [PMID: 18235012].
26. Haimovici R, Kramer M, Miller JW, Hasan T, Flotte TJ, Schomacker KT, Gragoudas ES. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 1997; 16:83-90. [PMID: 9068937].
27. Kramer M, Miller JW, Michaud N, Moulton RS, Hasan T, Flotte TJ, Gragoudas ES. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996; 103:427-38. [PMID: 8600419].
28. Zacks DN, Ezra E, Terada Y, Michaud N, Connolly E, Gragoudas ES, Miller JW. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci 2002; 43:2384-91. [PMID: 12091441].
29. Houle J-M, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002; 42:547-57. [PMID: 12017349].
30. Lu F, Hu Z, Sinard J, Garen A, Adelman RA. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2009; 50:3890-6. [PMID: 19357351].